ArticleEuropean journal of nuclear medicine and molecular imaging2026
Comparative assessment of KDIGO and CTCAE criteria for detecting renal function deterioration after peptide receptor radionuclide therapy.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRenal toxicity after peptide receptor radionuclide therapy (PRRT) is commonly assessed using Common Terminology Criteria for Adverse Events (CTCAE), whereas nephrological classification relies on Kidney Disease: Improving Global Outcomes (KDIGO)-based renal function categories. We compared CTCAE- and KDIGO-derived eGFR
methods149 gastroenteropancreatic neuroendocrine tumor patients scheduled for PRRT with renal follow-up for at least 12 months after treatment were included. Kidney function was assessed at baseline (BL), after the last cycle (LC) and last available follow-up (FU). Analyzing the time interval from BL to LC, estimated glomerular filtration rate (eGFR
resultsMedian eGFR
conclusionFor evaluation of renal safety under PRRT, clinically relevant KDIGO deterioration and CTCAE grading are not interchangeable. Clinically relevant KDIGO-derived eGFR
Indexed as
Identifiers
42584477What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.